MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » J&J’s medical device sales take a hit

J&J’s medical device sales take a hit

By

J&J's medical device sales take a hit

Johnson & Johnson‘s (NYSE:JNJ) medical device business posted top-line slides for both the 4th quarter and 2014, even excluding the effects of the strong dollar that helped to push down sales for the healthcare giant.

New Brunswick, N.J.-based J&J reported worldwide medical device sales of $6.65 billion for the 4th quarter, a 9% decline compared with the same period in 2013 and a 4.7% slide on a constant-currency basis. The division brought in full-year revenues of $27.52 billion, down 3.4% compared with the prior year and off 1.6% excluding currency effects.

"2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our medical devices business and are continuing our market leadership with iconic brands in our consumer business," chairman & CEO Alex Gorsky said in prepared remarks. "I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world."

Overall 4th-quarter profits fell about 28% to $2.52 billion, or 89¢ per share, including a $1.1 billion charge related to Johnson & Johnson’s $21.3 billion buyout of Synthes in 2012. Excluding 1-time items, J&J earned $1.27 per share, a penny above expectations on Wall Street. Total sales fell 0.6% to $18.25 billion for the quarter.

J&J forecast adjusted earnings of $6.12 to $6.27 per share for 2015, but said that it changed its definition of adjusted earnings to include after-tax amortization and special items. Include those, which J&J put at about 32¢, and the guidance becomes $5.80 to $5.95 per share, well below the The Street’s $6.16 consensus estimate.

Q4 sales were off -0.6% for J&J’s orthopedics business but up 2.8% on a constant-currency basis. U.S. orthopedics sales grew 2.4% and international sales slipped -4.1% (+3.3% CC).

JNJ shares were trading at $101.09 apiece in early-morning activity, down 2.8%.

Material from Reuters was used in this report.

In case you missed it

RSS From Medical Design & Outsourcing

  • Contract manufacturers fuel medtech expansion in Costa Rica
    Medical device manufacturing is flourishing in the Central American country, spurred by a host of incentives. This year is seeing a wave of expansions by medtech contract manufacturers in Costa Rica. Medtech OEMs have made the Central American company a manufacturing hub since the 1990s. Major companies operating there include Abbott, Bayer, Boston Scientific, Cardinal… […]
  • Purdue researchers develop biosensor for use during surgery
    Surgeons may soon be able to identify critical regions in tissues and organs during surgery using a biosensor recently developed at Purdue University. The biosensor can be printed in 3D using an automated printing system and allows for simultaneous recording and imaging of tissues and organs during surgery, according to its creator, Chi Hwan Lee.… […]
  • Amcor adds heat seal coating for medtech packaging
    Amcor has introduced a new heat seal coating for medical-grade DuPont Tyvek and paper packaging applications. The Buffalo Grove, Ill.-based company designed this next-generation coating technology to deliver enhanced performance features for healthcare applications. Amcor will produce the new coating, ACT2100, in multiple locations worldwide to offer customers the flexibility to receive supply from the… […]
  • Latest iCad 3D mammography AI gains CE mark
    iCad (NSDQ:ICAD) today announced that the third version of its ProFound AI for digital breast tomosynthesis (DBT) has won CE mark approval. Compared with previous software versions, the latest generation of ProFound AI offers up to a 10% improvement in specificity performance while maintaining a high sensitivity level and approximately 40% faster processing on the… […]
  • Device could reduce chemotherapy-induced pain
    Researchers in Singapore have partnered with Paxman Coolers (U.K.) to develop a device to prevent or reduce numbness and pain caused by chemotherapy. Chemotherapy-induced peripheral neuropathy (CIPN) is a severe side-effect of chemotherapy drugs called taxanes, which are used to treat common cancers such as breast, lung, ovarian and stomach cancer. CIPN affects about 1.4… […]
  • What medtech’s top executives learned from their dads
    For better or worse, parents including dads play a major role in who we become. With Father’s Day approaching in the U.S., Medical Design & Outsourcing and MassDevice reached out to some of medtech’s top executives to ask what they learned from their dads. Here’s what they said: “My father built a business in the… […]
  • FDA issues docs on medtech remanufacturing, servicing
    The FDA has issued two documents to help distinguish between remanufacturing and servicing of medical devices. One is a draft guidance written to clarify the activities that likely constitute the remanufacturing of a device. The other is a discussion paper on cybersecurity and medtech servicing. The guidance also describes the FDA’s current position on remanufacturing,… […]
  • HelixBind wins $3M grant for sepsis test
    HelixBind announced today it has landed a $3 million federal grant to help develop a test to diagnose bloodstream infections associated with sepsis. The FDA granted Breakthrough Device Designation to the RaPID/BSI test and platform in 2020. Boxborough, Mass.-based HelixBind’s RaPID platform can provide definitive identification and characterization of infections directly from a blood draw… […]
  • Supreme Court upholds Affordable Care Act again
    The U.S. Supreme Court has turned back a third Republican challenge to the Affordable Care Act (ACA), this time by a 7-2 vote. The latest challenge to the law popularly known as Obamacare came from Texas and other states, backed by the administration of former President Donald Trump. The justices ruled that the challengers lacked… […]
  • New monitor could diagnose pregnancy complications
    Researchers at the National Institutes of Health (NIH) have developed a prototype device that could potentially diagnose pregnancy complications by monitoring the oxygen level of the placenta. The device sends near-infrared light through the abdomen to measure oxygen levels in the arterial and venous network in the placenta. The method was used to study the… […]
  • Dabir Surfaces forges deal with Vizient
    Dabir Surfaces (Harwood Heights, Ill.) recently announced that it has landed a contract with group purchasing firm Vizient. Dabir also announced a deal with Premier this month.  The contract with Vizient, effective April 1, 2021, involves both OR products and patient care products. Dabir will provide powered overlay surfaces for patients at risk of developing pressure… […]

Leave a Reply